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Abstract
 
Given its population of CCR5-expressing, immunologically activated CD4
 
  
 
T cells, the gas-
trointestinal (GI) mucosa is uniquely susceptible to human immunodeficiency virus (HIV)-1
infection. We undertook this study to assess whether a preferential depletion of mucosal CD4
 
 
 
T cells would be observed in HIV-1–infected subjects during the primary infection period, to
examine the anatomic subcompartment from which these cells are depleted, and to examine
whether suppressive highly active antiretroviral therapy could result in complete immune re-
constitution in the mucosal compartment. Our results demonstrate that a significant and prefer-
ential depletion of mucosal CD4
 
  
 
T cells compared with peripheral blood CD4
 
  
 
T cells is seen
during primary HIV-1 infection. CD4
 
  
 
T cell loss predominated in the effector subcompart-
ment of the GI mucosa, in distinction to the inductive compartment, where HIV-1 RNA was
present. Cross-sectional analysis of a cohort of primary HIV-1 infection subjects showed that
although chronic suppression of HIV-1 permits near-complete immune recovery of the peripheral
blood CD4
 
  
 
T cell population, a significantly greater CD4
 
  
 
T cell loss remains in the GI
mucosa, despite up to 5 yr of fully suppressive therapy. Given the importance of the mucosal
compartment in HIV-1 pathogenesis, further study to elucidate the significance of the changes
observed here is critical.
Key words: primary HIV-1 • GALT • CD4
 
  
 
T cells
 
Introduction
 
The gastrointestinal (GI) mucosa harbors the majority
of the body’s lymphocytes compared with the peripheral
blood, which contains only 2–5% of all lymphocytes (1, 2).
In addition to representing the largest lymphoid organ, certain
characteristics of the mucosal compartment render it ex-
tremely permissive to HIV-1 infection and supportive of
HIV-1 replication. Compared with circulating lympho-
cytes, a greater percentage of these mucosal CD4
 
  
 
lympho-
cytes express the CCR5 chemokine coreceptor (3–8). The
percentage of mucosal CD4
 
  
 
cells that express the CXCR4
chemokine coreceptor is similar to that seen in the blood
(8). Additionally, due to its proximity to the external envi-
ronment and constant exposure to a myriad of food and
microbial antigens, a predominant number of GI mucosal
CD4
 
  
 
T cells are activated and well differentiated with a
memory phenotype (9, 10). Lastly, the GI mucosa is main-
tained in a state of physiological inflammation characterized
by a high percentage of proinflammatory, HIV-1–stimulatory
cytokines (11).
Increasing evidence suggests that virologic and immuno-
logic events during acute and early HIV-1 infection have a
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crucial role in determining the rapidity of clinical progres-
sion in infected individuals (4, 12). Because the GI tract is
an important route for HIV-1 entry and a potentially dom-
inant site of HIV-1 replication, it is vital that early GI mu-
cosal events be carefully examined to better understand the
pathogenesis of acute and early HIV-1 infection. Owing to
the difficulty in identifying patients during acute HIV-1 in-
fection and the added complexity of obtaining GI biopsy
samples in these patients, study of the mucosal events dur-
ing acute/early HIV-1 infection has to date been lacking,
and the majority of our current understanding is derived
from the simian immunodeficiency (SIV)-macaque model.
In the macaque model, acute SIV infection results in pro-
found depletion of mucosal CD4
 
  
 
T cells (2, 13–17) with
relative preservation of CD4
 
  
 
T cells in the peripheral
blood and lymph nodes over the first 3 wk. Mucosal CD4
 
 
 
T cell depletion is seen whether the inoculum was deliv-
ered parenterally (2, 3, 14) or mucosally (3, 15). A subset of
CD4
 
  
 
T cells that have a highly activated, memory pheno-
type are found to be the most significantly depleted (18).
Because mucosal sites abound in CD4
 
  
 
T cells with this
phenotype, the majority of CD4
 
  
 
T cell depletion in acute
SIV infection is confined to the mucosal compartment. Al-
though immunologic and virologic events during primary
SIV infection have been well described, mucosal events
have been described in only two primary HIV-1–infected
human subjects. These patients, infected for 4 and 6 wk, re-
spectively, showed depletion of mucosal CD4
 
  
 
T cells (19).
We undertook this study to characterize changes in the
GI tract in a cohort of patients with acute and early HIV-1
infection, and to understand the effects of treatment with
highly active antiretroviral therapy (HAART).
 
Materials and Methods
 
Patients and Sample Acquisition.
 
Peripheral blood and rectosig-
moid colonic mucosal tissue were collected from HIV-1–infected
and –uninfected subjects. A total of 27 HIV-1–infected and 10
HIV-1–uninfected subjects were studied. Of the HIV-1 infected,
19 subjects were identified during primary HIV-1 infection. Pa-
tients were all viremic and staged as per the National Institutes of
Health (NIH)-sponsored Acute and Early Disease Research Pro-
gram (AIEDRP) as follows: enzyme-linked immunosorbent assay
negative (stage Ia), Western blot indeterminate (stage Ib), or a de-
tuned ELISA (20) nonreactive (stage II) or a documented nega-
tive within 6 mo of presentation (stage III). Eight HIV-1–infected
subjects were studied during the chronic stage of HIV-1 infec-
tion. The primary infection cohort was subgrouped as follows
(see Table I): group 1: HAART naive, newly diagnosed subjects
(
 
n 
 
  
 
11), as well as two subjects who were treated with HAART
for 1 wk before biopsy; and group 2: HIV-1–infected subjects,
identified during the primary infection stage and had received
HAART for up to 5 yr (
 
n 
 
  
 
8). Group 2 is comprised of subjects
who had received HAART for 6 mo (
 
n 
 
  
 
2), 1 yr (
 
n 
 
  
 
2), 2 yr
(
 
n 
 
  
 
2), 3 yr (
 
n 
 
  
 
1), and 5 yr (
 
n 
 
  
 
1). There was no difference
between groups 1 and 2 with respect to CD4
 
  
 
T cell count on
presentation (P 
 
  
 
0.5), log
 
10 
 
HIV-1 viral load on presentation (P 
 
 
 
0.7), or the estimated duration of infection on presentation (P 
 
 
 
0.1). The mean age for primary infection subjects was 35 yr. All
subjects contracted HIV-1 sexually during same sex contact. Sub-
jects were treated with a multidrug regimen consisting of combi-
nations of nucleoside (nucleotide) reverse transcriptase inhibitors
with either a ritonavir-boosted protease inhibitor and/or a non-
nucleoside reverse transcriptase inhibitor.
All eight subjects, five women and three men, identified during
chronic HIV-1 infection were not receiving HAART at the time
of biopsy. The mean age of this group was 38 yr. The risk factors
for HIV acquisition in this group included heterosexual sex (
 
n 
 
 
 
4), homosexual sex (
 
n 
 
  
 
2), and intravenous drug abuse (
 
n 
 
  
 
2).
The mean CD4
 
  
 
T cell count in this group was 216 cells/mm
 
3
 
,
with a mean log
 
10 
 
plasma HIV-1 RNA level of 4.7 copies/ml.
The 10 HIV-1–uninfected subjects were recruited from a popula-
tion undergoing routine screening colonoscopy. This group was
comprised of six men and four women. None of the HIV-1–
infected or –uninfected subjects was found to have macroscopic
evidence of GI mucosal disease, nor were any concomitant patho-
logical processes found on histological examination. All enrolled
subjects signed an informed consent form that was approved by
the institutional review boards of The Rockefeller University,
Bellevue Hospital Center, and Manhattan Veteran’s Administra-
tion Center. All clinical investigation was conducted according to
the principles expressed in the Helsinki Declaration.
Endoscopic biopsies were obtained from the colon from mac-
roscopically normal mucosa at a standardized site in the rectosig-
moid region 30–40 cm from the anal margin. This site was cho-
sen for all sampling to avoid potential regional variation and the
potential for confounding effects from infectious or traumatic
proctitis that would be expected to occur distal to this location.
Biopsies were taken using large-cup endoscopic biopsy forceps
(outside diameter, 3.3 mm; Microvasive Radial Jaw; Boston Sci-
entific) and (a) immediately placed in tissue culture medium
(RPMI 1640; Mediatech Inc.), (b) placed into 2-ml prelabeled
cryovials (Nalgene) and frozen in liquid nitrogen, or (c) placed in
formalin to preserve tissue architecture. Formalin-fixed tissues
were washed with PBS, transferred to 100% alcohol, and pro-
cessed for immunohistochemistry and in situ hybridization. Phle-
botomy was undertaken immediately before endoscopy.
Immediately after acquisition, mucosal mononuclear cells (MMCs)
were enzymatically isolated from mucosal biopsies using a 30-min
incubation in collagenase type II (Clostridiopeptidase A; Sigma-
Aldrich) followed by mechanical separation through a blunt-
end, 16-gauge needle. The digested cell suspension was strained
through a 70-
 
 
 
m disposable plastic strainer. Immediately after
isolation, cells were washed with PBS and resuspended in PBS
containing antibodies for flow cytometry. PBMCs were prepared
by centrifugation on a Ficoll-Hypaque density gradient (Media-
tech). PBMCs were stained for flow cytometry immediately after
isolation.
 
Flow Cytometry.
 
Cell surface expression of lymphocyte anti-
gens was identified by monoclonal antibody staining of freshly
isolated MMCs and PBMCs, followed by flow cytometry using
a FACSCalibur (Becton Dickinson Immunocytometry Systems
[BDIS]) with analysis using CELLQuest software (BDIS). Mono-
clonal antibodies used in this study included anti–human CD3
FITC (clone UCHT1; BDIS), anti–human CD3-PE (clone
SK-7; BDIS), anti–human CD3–peridinin chlorophyll-
 
a 
 
protein
(clone SK-7; BDIS), anti–human CD4-allophycocyanin (clone
RPA T4; BD Biosciences), anti–human CD8 PE (clone RPA
T8; BD Biosciences), anti–human CXCR4-PE (clone 12G5; BD
Biosciences), and anti–human CCR5-FITC (clone 2D7/CCR5;
BD Biosciences). During flow cytometry, lymphocytes, initially
identified by their forward and side scatter characteristics, were
subject to phenotypic analysis. Dead cells were excluded from 
Mehandru et al.
 
763
 
analysis using 7-aminoactinomycin D (Calbiochem). To deter-
mine the percentages of CD4
 
  
 
and CD8
 
  
 
cells in the T cell pop-
ulation, gated lymphocytes were initially examined for the ex-
pression of CD3. The CD3
 
  
 
lymphocytes were then analyzed for
expression of CD4 and CD8 receptors. To evaluate the expres-
sion of chemokine coreceptors, gated lymphocytes were initially
examined for the expression of CD4 receptor. The CD4
 
  
 
lym-
phocytes were further examined for the expression of chemokine
coreceptors CCR5 and CXCR4.
 
Light Microscopy and Immunohistochemistry.
 
For light micro-
scopic evaluation, tissues were fixed in 4% neutral-buffered forma-
lin and embedded in paraffin. 5-
 
 
 
m thick sections were cut and
stained with hematoxylin and eosin and Giemsa stains. Immuno-
histochemistry was also performed on paraffin-embedded sections
after high temperature antigen retrieval as described previously
(21). The following antibodies were used according to the manu-
facturer’s instructions: NCL-CD4-IF6 (anti-CD4 antibody; No-
vocastra) and C8/144B (anti-CD8 antibody; Dakopatts). Binding
of antibodies was visualized by the alkaline phosphatase/antialka-
line phosphatase method using new fuchsin as a chromogen.
 
In Situ Hybridization.
 
The in situ hybridization was per-
formed on paraffin sections as described previously (21). In brief,
5-
 
 
 
m sections were cut onto slides coated with 3-amino-propyl-
trietho-silane. Dewaxed paraffin-embedded sections were either
boiled in a domestic pressure cooker in citrate buffer (pH 6.0) for
5 min or treated with 0.01 mg/ml proteinase K for 8 min at
room temperature and subjected to in situ hybridization to detect
viral RNA. We used a 
 
35
 
S-labeled, single stranded antisense
RNA probe of HIV-1 (Lofstrand Labs). The probe was com-
posed of fragments of 1.4–2.7 kb, which collectively represent
 
 
 
90% of the HIV-1 genome (22). The specific activity of the
probe was 2 
 
  
 
10
 
6 
 
dpm of probe/milliliter. The hybridization
was performed overnight at 45
 
 
 
C in a moist chamber. The slides
were washed, digested with RNase (Boehringer) at 37
 
 
 
C for 40
min, and washed again. The slides were then dipped into photo
emulsion (NTB2; Eastman Kodak Co.), exposed for 7 d, devel-
oped, counterstained with hematoxylin, and mounted. As a posi-
tive control, paraffin-embedded sections from the spleen of an
HIV-infected patient were used. As a negative control, sections
were hybridized with a 
 
35
 
S-labeled sense probe.
 
Quantitative Analysis of HIV RNA
 
  
 
Cells, CD4
 
  
 
Cells, and
CD8
 
  
 
Cells.
 
The autoradiographs were examined with a mi-
croscope equipped with epiluminescent illumination (Axiophot;
Carl Zeiss MicroImaging, Inc.), a 3CD camera, and a PC-based
image analysis system (KS 4000; Kontron). Cells were considered
positive for viral gene expression if the grain count was more
than six times the background. The positive cells were counted.
The area occupied by lymphoid follicles was measured and the
frequency of RNA-producing cells per mm
 
2 
 
of gut-associated
lymphoid tissue (GALT) was calculated. To evaluate the number
and distribution of T cell subsets, transmission light was used. Us-
ing a 40
 
  
 
objective, a standard area was set by the image ana-
lyzer. The number of positive cells within this unit area was de-
termined by manual counting. For the lamina propria, a total of
10–15 consecutive nonoverlapping fields was analyzed for each
staining. For the GALT, two to five representative areas were
chosen. The individual values obtained with each T cell marker
were then pooled and the mean numbers of positive cells per unit
area of lamina propria or GALT were determined separately.
 
Statistical Methodology.
 
Values are expressed as mean 
 
  
 
stan-
dard deviation. Statistical comparisons were made between
PBMCs and MMCs from individuals using a paired 
 
t 
 
test. Statisti-
cal comparisons were made between HIV-1–infected and control
subjects using a two-sample, unequal variance 
 
t
 
 test. All reported
p-values were two-sided at the 0.05 significance level using Win-
dows software (SPSS 11.0; SPSS Inc.).
 
Results
 
Primary HIV-1 Infection Is Associated with a Preferential
Depletion of mucosal CD4
 
  
 
T Cells.
 
Isolated MMCs and
PBMCs from all subjects were examined using flow cy-
tometry to determine the percentage of CD4
 
  
 
T cells (Fig.
1 A). The percentage of mucosal T cells expressing CD4 was
significantly less than the percentage of CD4
 
  
 
T cells in the
peripheral blood in every patient in this group (Fig. 1 B).
When cumulative data from group 1 was analyzed, the
mean mucosal CD4
 
  
 
T cell percentage was 15.7 
 
  
 
3.6, and
was significantly less than the mean CD4
 
  
 
T cell percent-
Figure 1. CD4  T cells are preferentially depleted in the GI tract in
acute and early HIV-1 infection. PBMCs and MMCs from the rectosigmoid
region from group 1, acute and early HIV-1 infection subjects (n   13), and
HIV-1–uninfected controls (n   10) were analyzed by flow cytometry.
CD3  gated lymphocytes were analyzed for the expression of CD4 and
CD8. (A) A representative flow plot from subject 105 is depicted. CD8 
T cells are shown on the x axis and CD4  T cells are shown on the y axis.
(B) Comparison of CD4  T cells in the blood and GI tract of all 13 group
1 primary infection subjects. The percent of CD4  T cells is shown in
PBMCs (gray) and MMCs (white) per study subject. (C) Comparison of
the mean percent of CD4  T cells in the PBMCs of HIV-1–uninfected
controls (black bar) and group1 subjects (gray bar), and MMCs of HIV-1–
uninfected controls (hatched bar) and group 1 subjects (white bar). 
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age in the peripheral blood (42.3 
 
  
 
14.7; P 
 
  
 
0.001). The
mean CD4/CD8 ratio in the MMCs (0.2 
 
  
 
0.04) was also
significantly lower than the mean CD4/CD8 ratio in the
circulating PBMC compartment (0.9 
 
  
 
0.6; P 
 
  
 
0.002). In
HIV-1–uninfected individuals, the percentage of CD4
 
  
 
T
cells in the mucosa (56.4 
 
  
 
8.8%) and blood (59.6 
 
 
 
14.3%) were not significantly different (P 
 
  
 
0.24), and the
CD4/CD8 ratios in the mucosa and blood were 1.3 
 
 
 
0.5% and 1.7 
 
  
 
0.7%, respectively.
Comparison of the percentages of CD4
 
  
 
T cells in the
mucosa of HIV-1–uninfected and newly diagnosed subjects
with primary HIV-1 infection (group 1) revealed highly
statistically significant differences with marked depletion in
the HIV-1–infected group (P 
 
  
 
0.001; Fig. 1 C). As ex-
pected, depletion of peripheral blood CD4
 
  
 
T cells was also
observed when newly diagnosed, primary HIV-1–infected
subjects were compared with HIV-1–uninfected subjects.
However, the differences between the two groups were
much less marked, though still significant (P 
 
  
 
0.01).
 
Primary HIV-1 Infection Is Associated with Preferential De-
pletion of CCR5-expressing Mucosal CD4  T Cells. The
majority of GI MMCs express CCR5, either alone or along
with CXCR4 (4, 8). Given the high expression of CCR5
in the mucosa and the possibility that the mucosal environ-
ment plays an important role in the selection of the CCR5-
tropic strains of HIV-1 that predominate in the blood dur-
ing the primary infection period, we sought to determine
the effect of primary HIV-1 infection on CCR5-expressing
CD4  MMCs. Using four-color flow cytometry, we quan-
tified the percentage of CD3 /CD4  MMCs and PBMCs
that expressed CCR5, CXCR4, or coexpressed CCR5 and
CXCR4. Comparison was made between HIV-1–unin-
fected subjects and the untreated primary HIV-1 infection
subjects (group 1). In general there was no difference in lev-
els of CD3 /CD4  cells expressing CCR5, CXCR4, or
both in the peripheral blood of uninfected controls when
compared with subjects in group 1 (Fig. 2 A). Mean levels
of CD4  PBMC populations that expressed CXCR4 were
64.3   15.2% in the HIV-1–uninfected subjects compared
with 63.7   11.8% in group 1 primary HIV-1 infection
subjects (P   0.6). Levels of CD3 /CD4  PBMCs express-
ing CCR5 were 18.7   9.0% in HIV-1–uninfected subjects
compared with 14.8   11.0% in group 1 (P   0.4). Levels
of CD3 /CD4  PBMCs coexpressing CCR5 and CXCR4
were 9.6   5.8% in HIV-1–uninfected subjects versus 6.9  
8.1% in group 1 primary HIV-1 infection subjects (P  
0.4). In comparison, analysis of CD4  mucosal T cells re-
vealed significant depletion in the HIV-1–infected subjects
that was most prominent in the CD3 /CD4  CCR5-
expressing populations. Although there was only a minor
degree of depletion of mucosal CD4  T cells expressing
CXCR4 (76.3   14.4% in HIV-1–uninfected subjects vs.
61.7   10.9 in group 1 subjects; P   0.03), the percentage
of cells expressing CCR5 alone was 73.5   13.4% in HIV-
1–uninfected subjects versus 42.5   18.9% in group 1 (P  
0.001). The most significant depletion was noted in the
population of CD4  mucosal T cells that coexpressed CCR5
and CXCR4. In the uninfected individuals, 56.2   13.9%
of the CD4  mucosal T cells coexpressed CCR5 and CXCR4
compared with just 21.1   14.3% in the group 1 subjects
(P   0.001; Fig. 2 B).
CD4  T Cells Are Preferentially Depleted from the Effector
Sites in the GI Mucosa. Having shown that the percentage
of CD4  T cells is decreased in acute and early HIV-1 in-
fection, we went on to examine the absolute number of
CD4  T cells in the GI biopsies. Using immunohistochem-
istry, paraffin-embedded mucosal biopsies were compared
between HIV-1–uninfected individuals and subjects with
acute and early HIV-1 infection. To classify the anatomic
subcompartment where CD4  T cell depletion occurred,
inductive and effector sites were examined separately.
The inductive sites or lymphoid nodules consisted of a
centrally located B cell–dependent area with or without a
germinal center (Fig. 3 A). The follicle-associated epithe-
lium and the dome area were noted in only a few of the sec-
tions examined. The B cell follicle was surrounded by the
T-dependent zone, similar to that seen in the paracortex of a
lymph node. In subjects with acute and early HIV-1 infec-
tion (Fig. 3 B) and in HIV-1–uninfected controls (Fig. 3 C),
the T cell zone was densely populated with CD4  T cells. In
comparison, significantly more CD8  T cells were noted in
the subjects with acute and early HIV-1 infection (mean:
130 cells/unit area; range: 95–137 cells/unit area) compared
Figure 2. CD4  T cells expressing CCR5 are preferentially depleted
from the GI tract in acute and early HIV-1 infection. PBMCs (A) and
MMCs (B) from the rectosigmoid region from individuals with acute and
early HIV-1 infection (group 1, n   13) and HIV-1–uninfected controls
(n   10) were analyzed by flow cytometry. CD3 /CD4  gated lympho-
cytes were analyzed for the expression of CXCR4, CCR5, or CCR5/
CXCR4. HIV-1–uninfected PBMCs (black bars), group 1 PBMCs (gray
bars), HIV-1–uninfected MMCs (hatched bars), and group 1 MMCs
(white bars) are shown. Mean percent of CD4  T cells expressing
chemokine receptors are depicted on the y axis and chemokine corecep-
tors CXCR4, CCR5, and CCR5/CXCR4 are grouped on the x axis.Mehandru et al. 765
with the HIV-1–uninfected controls (mean: 83 cells/unit
area; range: 81–140 cells/unit area). The mean CD4/CD8
ratio in the inductive sites of HIV-1–uninfected controls was
2.4 (range 1.6–3.1). In comparison, the mean CD4/CD8 ra-
tio in the inductive sites of subjects with acute and early
HIV-1 infection was 1.3 (range 0.9–2.0). It is important to
note that the lower CD4/CD8 ratio in HIV-1–infected sub-
jects was due to an increase in the number of CD8  T cells
and not due to a depletion of the CD4  T cells.
Significant CD4  T cell depletion was noted in the ef-
fector sites in subjects with acute and early HIV-1 infection
(Fig. 3 D) compared with HIV-1–uninfected controls (Fig.
3 E). In this site, the mean CD4/CD8 ratio was 0.4 (range
0.1–0.7) in the HIV-1–infected subjects and 1.5 (1.1–2) in
the HIV-1–uninfected controls (Fig. 3 F).
HIV-1 RNA Is Located within the Inductive Sites of the GI
Mucosa. Having shown that depletion of mucosal CD4 
T cells was primarily noted in the effector compartment,
we sought to determine whether this anatomic subcom-
partment was also the principal site of viral replication. In
situ hybridization was performed to localize HIV-1 RNA
within the effector and inductive subcompartments of the
GI mucosa. Cells expressing HIV-1 RNA were predomi-
nantly localized to the organized lymphoid follicles or the
inductive sites of the GI mucosa (Fig. 4, A and B), present
both in the T cell zone and the germinal centers. Even
though CD4  T cells were depleted in the effector sites, of
the CD4  T cells that remained, productively infected cells
were either absent or very rare. Interestingly, no viral trap-
ping by follicular dendritic cells was noted in the biopsies
of the group 1 primary infection subjects.
Reconstitution of CD4  MMCs Is Incomplete Despite Sup-
pressive Antiretroviral Therapy. To examine whether appar-
ently suppressive HAART would result in reconstitution
of CD4  MMCs, as has been described among CD4 
PBMCs, subjects in whom HAART was initiated during
acute and early HIV-1 infection were examined. We
performed a cross-sectional analysis of primary HIV-1–
infected subjects who had been treated with regimens con-
taining three or four drug combinations for varying dura-
Figure 3. Effector sites (lamina pro-
pria) of the GI tract show the most pro-
nounced CD4  T cell depletion in acute
and early HIV-1 infection. Immunohis-
tochemical characterization of the effector
and inductive sites in the rectal biopsies.
Using a PC-based image analysis system
(KS 4000; Kontron), a standard area was
set by the image analyzer. For the lamina
propria, a total of 10–15 consecutive
nonoverlapping fields were analyzed for
each staining. For the GALT, two to
five representative areas were chosen.
(A) At a magnification of 25, a Giemsa-
stained section is shown depicting a
lymphoid nodule (inductive site) where
the germinal center (GC) and T cell
zone (T) are indicated. The effector
compartment represented by the lamina
propria (LP) is seen in the lower part of
the section. (B and C) The inductive
sites are densely populated with CD4  T
cells (stained red) in both group 1 (B)
and HIV-1–uninfected (C) subjects. A
magnification of 100. (D and E) Effector
sites in acute and early HIV-1 infection
(D) show significant depletion of CD4 
T cells (stained red) compared with
HIV-1–uninfected controls (E). A mag-
nification of 100. (F) In the inductive
and effector compartments, the mean of
CD4  and CD8  T cells per unit area
was determined and the CD4/CD8 ratio
was calculated. A comparison of the
mean CD4/CD8 ratio (represented on
the y axis) between HIV-1–uninfected
(gray bars) and group 1 subjects (white
bars) is shown.Primary HIV-1 Infection CD4  T Cell Depletion Gastrointestinal Tract 766
tions (n     8), and eight untreated HIV-1–infected
subjects biopsied during chronic HIV-1 infection. The
primary HIV-1 infection cohort included two subjects from
group 1 who had been treated with suppressive HAART
for 6 mo, two subjects who had been treated with suppres-
sive HAART for 1 yr, two subjects who had been treated
with suppressive HAART for 2 yr, and two subjects each
treated for 3 and 5 yr, respectively. The mean percentage
of CD4  T cells in the peripheral blood in this group was
51.3   11.3%, whereas in the GI mucosa, it was 35.4  
7.8% (P   0.008; Fig. 5). When the percentage of CD4  T
cells of these subjects was compared with that from HIV-
1–uninfected subjects, there was a significant difference in
the mucosal compartment (P   0.001), even though the
difference in the blood was no longer statistically significant
(P   0.06). The mean CD4/CD8 ratio in the mucosal
compartment (0.6    0.2) continued to be significantly
lower than the CD4/CD8 ratio in the blood compartment
(1.3   0.7) of HAART-treated primary infection subjects
(P   0.03).
To better understand the effect of HAART in this di-
verse group, we analyzed each patient individually (Table
II). In the two subjects (100-6m and 336-6m) followed
longitudinally for 6 mo, the CD4/CD8 ratio in the blood
showed significant improvement over baseline with treat-
ment (0.6 in the untreated stage to 1.1 after 6 mo of
HAART in both subjects). However, the CD4/CD8 ratio
in the GI tract continued to be low (0.4 and 0.5, respec-
tively). In subjects 78 and 132, the CD4/CD8 ratio in the
blood and GI tract equalized but continued to be lower
than the mean CD4/CD8 ratio in the blood (1.7   0.6)
and mucosa (1.3   0.4) of HIV-1–uninfected controls. It is
of interest that these two subjects had initiated HAART af-
ter 28 and 26 d, respectively, of their estimated dates of in-
fection (Table I). In subjects 106 and 923, the CD4/CD8
ratio in the GI tract continued to be significantly lower
compared with the blood, despite treatment with HAART
for 3 and 5 yr, respectively. These two subjects had initi-
ated HAART after 168 and 204 d, respectively, of their es-
timated date of infection (Table I). Notably for subject 56,
the CD4/CD8 ratio in the blood normalized to 2.9 with
fully suppressive HAART for 2 yr. In comparison, the
CD4/CD8 ratio in the GI tract remained considerably
lower at 0.8.
As expected, in chronic, untreated HIV-1–infected sub-
jects, the mean CD4  T cell percentage continued to de-
cline in both the blood (15.3   17%) and mucosal (12.5  
11%) compartments (Fig. 5).
Discussion
Being that the GI tract is the largest lymphoid organ in
the body, it would follow that the potential for deleterious
effects of HIV-1 infection would be great at this site. Al-
though the effect of primary HIV-1 infection on lympho-
cyte populations in the peripheral blood has been well
characterized, the events associated with primary HIV-1
infection in GI mucosal lymphocyte populations in man
has to date remained largely unknown. Given the strong
selection pressure for CCR5 coreceptor using viruses dur-
ing transmission of HIV-1 (23), it would be likely that the
sizable population of CCR5-expressing, immunologically
activated CD4  T cells in the GI mucosa would be more
supportive of viral replication and susceptible to its delete-
rious effects as compared with the peripheral blood where
the T cells are predominantly CCR5  and naive (8). We
undertook this study to assess whether a preferential deple-
tion of mucosal CD4  T cells would be observed in pri-
Figure 4. HIV-1 RNA is localized in the organized lymphoid follicles
of the GI tract in subjects with acute and early HIV-1 infection. In situ
hybridization was performed using a 35S-labeled, single stranded antisense
RNA probe as described in Materials and Methods. Cells expressing
HIV-1 RNA (arrows) are present in the germinal center and T cell zone.
A magnification of 40.
Figure 5. Prolonged HAART results in only partial reconstitution of
the GI tract CD4  T cells. PBMCs and MMCs from the rectosigmoid
region from HIV-1–uninfected individuals (n   10), subjects with acute
and early HIV-1 infection (n   13), subjects with HIV-1 infection treated
during the primary infection stage (n   8), and chronically infected HIV-1–
untreated subjects (n   8) were analyzed by flow cytometry. The mean
percent of CD4  T cells is shown in PBMCs (gray bars) and MMCs
(white bars) per study group.Mehandru et al. 767
mary HIV-1–infected subjects as has been observed in the
SIV-macaque model. We went on to examine the ana-
tomic subcompartment from which these cells are de-
pleted and examine whether suppressive HAART therapy
could result in complete immune reconstitution in the
mucosal compartment.
Previous studies of the effect of HIV-1 on the GI mu-
cosal CD4  T cells during the primary infection period
have been limited to a single report, with two subjects
studied during early HIV-1 infection. In both of these indi-
viduals, identified after 4 and 6 wk of the estimated date of
infection, mucosal CD4  T cell depletion was noted (19).
The remaining data suggesting the GI tract as the preferred
site for virus replication and CD4  T cell depletion are de-
rived from studies examining primary infection of macaques
with SIV (2, 3, 13, 15, 17, 18, 24, 25).
Table I. Patient Characteristics
Study Stagea
CD4  T cell count
(cells/mm3)
Log10 plasma HIV-1
(copies/ml)
Estimated duration of infectionb
(days) Duration of HAART
prior to biopsy
(days) At presentation At biopsy At presentation At biopsy At presentation Prior to HAART initiation
Group 1
102 Ia 395 391 6.9 7.1 18 NA NA
100 II 610 595 5.8 5.5 45 NA NA
104 II 981 1,321 6.0 5.8 38 NA NA
107 Ia 456 426 6.1 5.6 24 NA NA
336 II 556 556 5.0 5.0 62 NA NA
109 II 340 340 6.3 6.3 19 NA NA
119 Ia 248 248 6.9 6.3 18 NA NA
122 III 285 400 5.1 4.9 72 NA NA
125 II 830 684 5.8 5.0 36 NA NA
127 Ia 390 350 4.8 4.9 23 NA NA
131 Ia 250 349 6.7 6.6 25 NA NA
105 Ia 374 462 7.1 4.7 27 7 7
106 Ia 317 368 6.8 5.4 26 7 7
Group 2
100-6m II 610 698 5.8  1.7 45 76 214
336-6m II 556 996 4.9  1.7 48 90 229
64 Ia 846 994 7.2  1.7 28 31 398
78 II 175 460 7.4  1.7 26 28 392
56 II 619 752 5.4  1.7 61 71 670
132 II 366 657 6.1  1.7 19 26 763
106 III 351 595 6.9  1.7 157 168 1,182
923 Ia 698 939 5.1  1.7 201 204 1,932
aSubjects were staged as per the NIH-sponsored AIEDRP as follows: enzyme-linked immunosorbent assay negative (stage Ia), Western blot indeter-
minate (stage Ib), or a detuned ELISA nonreactive (stage II) or a documented negative within 6 mo of presentation (Stage III).
bThe approximate date of infection was calculated as follows: 2 wk before the onset of acute retroviral illness (97%); in cases where no acute retroviral
illness symptoms were experienced, the midpoint between the last negative antibody result and first positive Western blot result was determined.
Table II. Comparison of Blood and GI Tract Reconstitution 
with HAART
Subject
CD4/CD8 ratio
in the blood
CD4/CD8 ratio
in the GI tract
Duration of HAART
at the time of biopsy
100-6m 1.1 0.4 6 mo
336-6m 1.1 0.5 6 mo
64 1.6 0.6 1 yr
78 0.7 0.7 1 yr
56 2.9 0.8 2 yr
132 0.7 0.8 2 yr
106 0.9 0.5 3 yr
923 1 0.5 5 yrPrimary HIV-1 Infection CD4  T Cell Depletion Gastrointestinal Tract 768
Here we have described 13 subjects who are identified
and studied extremely early in the course of HIV-1 infec-
tion. We have confirmed that indeed, significant mucosal
CD4  T cell depletion occurs in subjects during primary
HIV-1 infection, before changes seen in the peripheral
blood. However, human mucosal CD4  T cell depletion
appears to be less marked than that described in primary
SIV infection, where the percentage of CD4  T cells in the
macaque small bowel was reduced to  10% by 3 wk after
infection (13). This is likely explained by a difference in the
site sampled. All the biopsies in our studies were obtained
from the rectal mucosa, which has both effector and induc-
tive lymphoid tissue. In the macaque models described, the
biopsies are usually obtained from the proximal jejunum,
which is devoid of immune inductive sites (26). As a result,
samples obtained from the jejunum in macaque models
may demonstrate a much higher degree of CD4  T cell de-
pletion compared with what is noted in this study. There
may also be other factors responsible. SIV is introduced in
large inocula to attempt to guarantee infection. Simian
AIDS is characterized by an accelerated natural history of
the disease (27, 28) and is accompanied by higher peak
plasma viral levels (29, 30) when compared with HIV-1 in-
fection in man. Also, SIV is known to use alternative and
additional coreceptors when compared with HIV-1 (31,
32), which may account for apparent differences in replica-
tion dynamics. Yet unexplained differences may also exist
in host susceptibility to the two infections.
In addition to confirming the numerical decrease in mu-
cosal CD4  T cell percentage, we have gone on to charac-
terize the relationship between CD4  T cell depletion and
HIV-1 RNA localization within specific anatomic sub-
compartments of the GI mucosa. Like the small intestine,
the immune compartment in the rectal mucosa is also di-
vided into inductive and effector arms (24, 33). The orga-
nized lymphoid tissue with a high content of CD68  MHC
class II  macrophages and cells expressing costimulatory
molecules CD86 and CD40 serves as an antigen-presenting
site (24). The majority of lymphocytes present in the in-
ductive compartment are antigen naive. However, once
activated and primed by antigen-presenting cells such as
dendritic cells, GI mucosal lymphocytes can home back to
the mucosa to perform effector functions (34). The lamina
propria lymphocytes, which are comprised of a high per-
centage of differentiated effector cells (9, 10), serve as the
effector arm of the mucosal immune system (33). A limited
number of studies have described the effects of SIV infec-
tion (24–26) and chronic and advanced HIV-1 infection
(35) on these distinct, anatomic subcompartments. Our re-
sults suggest that as early as the primary infection stage,
there is a depletion of CD4  T cells from the effector com-
partment of the GI mucosa. Given the activated and differ-
entiated phenotype of these cells, direct cytopathic effects
of the HIV-1 virus could be one mechanism explaining this
lesion. To assess this, we performed in situ hybridization
for HIV-1 RNA to localize the sites of HIV-1 replication
in the GI mucosa. We observed that HIV-1 RNA was lo-
calized in the inductive compartment of the mucosa. These
findings are consistent with the SIV-macaque model where
during early infection, most of the SIV-infected cells are
located in the inductive sites. In a recent study, Veazey et
al. (26) noted that very early in the course of infection, i.e.,
from 7 to 14 d after infection, SIV-infected cells could be
localized in the effector compartment as well. However,
once effector CD4  T cells were depleted, SIV RNA was
predominantly seen in the inductive compartment. Our
patients, although studied extremely early in the course of
HIV-1 infection, had already developed profound CD4  T
cell depletion in the effector sites. Thus, one possible ex-
planation for the localization of HIV-1 RNA only in the
inductive compartment is the loss of target cells from the
effector sites by the time the biopsies were performed.
Further studies are underway to better characterize the
dynamics of CD4  T cell loss noted in the effector com-
partment. Some of the possibilities include decreased local
proliferation, increased cell death in the effector compart-
ment due to apoptosis or activation-induced cell death
(36), reduced homing of cells to the effector site from the
periphery after antigen recognition due to either direct cy-
topathic effects of HIV-1 or immune activation-induced
cell death, or perhaps combinations of the above (37).
By studying subjects in whom treatment was initiated
during acute and early HIV-1 infection, we sought to un-
derstand whether HAART would result in mucosal CD4 
T cell reconstitution. Guadalupe et al. (19) showed that in
one subject, mucosal CD4  T cell reconstitution was at-
tained when HAART was initiated within 6 wk of the es-
timated date of infection. In comparison, we did not see
immune reconstitution in the GI mucosa with HAART in
our study population. It is to be noted that all eight patients
studied initiated therapy in the primary infection stage, re-
mained compliant with treatment, and continued to have
undetectable plasma HIV-1 RNA levels for the entire du-
ration of the study period. The cohort remains small and
we plan to study more subjects longitudinally to better as-
sess the degree of immune reconstitution and the factors
that may predispose to a greater or lesser response.
The consequence of early depletion and incomplete re-
constitution of mucosal CD4  T cells is unclear. Although
opportunistic infections remain rare until the peripheral
CD4  T cell count falls during the chronic infection pe-
riod, the long-term outcome of treated HIV-1 infection
remains unknown. Furthermore, the nature of the CD4  T
cell loss requires additional study. Theoretically, the loss of
specific clones of CD4  T cells in the mucosa may predis-
pose to accelerated immune senescence, more rapid than
that seen as a consequence of aging, which in turn may re-
sult in the increased incidence of malignancies, be they
lymphomas or solid tumors such as adenocarcinomas.
Given the importance of the mucosal compartment in
HIV-1 pathogenesis, our findings may have important im-
plications with regard to treatment. Perhaps efforts to spe-
cifically inhibit T cell activation in the GI tract as well as
drugs to more specifically interfere with HIV-1 entry (38,Mehandru et al. 769
39) and replication in the GI mucosa during the primary
infection period may result in lowering of the viral set
point and in conjunction with HAART, result in improve-
ment in clinical outcome. Such investigations are clearly
needed as the goal of optimized treatment of HIV-1 infec-
tion is yet to be attained.
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